¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Polymorphism, Restriction Fragment Length"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
  • polymorphism
    ´ÙÇüÅÂ, ¹µÇüÅÂ, ¿©·¯ÇüÅÂ
  • single nucleotide polymorphism
    ´ÜÀÏ´ºÅ¬·¹¿ÀƼµå´ÙÇüÅÂ
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • acentric fragment
    ¹«Áß½ÉÀýÁ¶°¢, ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • asymmetric fetal growth restriction
    ºñ´ëĪžƼºÀåÁ¦ÇÑ
  • bone fragment
    »ÄÁ¶°¢, °ñÆí
  • Fc fragment
    FcºÐÀý
  • fallen fragment sign
    ³«ÇÏÆÄÆí¡ÈÄ
  • fracture fragment
    °ñÀýÁ¶°¢, °ñÀýÀýÆí
  • fragment
    Á¶°¢, Æí
  • genetic restriction
    À¯Àü»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁ¦ÇÑ
  • restriction
    Á¦ÇÑ
  • restriction endonuclease
    Á¦ÇÑÇÙ¼ÓÇÙ»êºÐÇØÈ¿¼Ò, Á¦ÇÑ¿£µµ´ºÅ¬·¹¾ÆÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • length
    ±æÀÌ
  • polymorphism
    ´ÙÇüÅÂ, ¿©·¯ÇüÅÂÁõ
  • fragment
    Á¶°¢
  • bone fragment
    »ÄÁ¶°¢
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • restriction
    Á¦ÇÑ
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁö¿¬
  • salt restriction
    ¿°ºÐÁ¦ÇÑ
  • water restriction
    ¹°Á¦ÇÑ, ¼öºÐÁ¦ÇÑ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
  • polymorphism
    ´ÙÇüÅÂ, ¿©·¯ÇüÅÂÁõ
  • acentric fragment
    ¹«Áß½ÉÀýÁ¶°¢, ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • bone fragment
    »ÀÁ¶°¢, °ñÆí
  • fragment
    Á¶°¢
  • fallen fragment sign
    ³«ÇÏÆÄÆí¡ÈÄ
  • fracture fragment
    °ñÀýÁ¶°¢, °ñÀýÀýÆí
  • restriction endonuclease
    Á¦ÇÑÀûÇÙ¼ÓÇÙ»êºÐÇØÈ¿¼Ò, Á¦ÇÑÀû¿£µµ´ºÅ¬·¹¾ÆÁ¦
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • genetic restriction
    À¯ÀüÀû»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • haplotype restriction
    ÀϹè¼öüÁ¦ÇÑ
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • restriction
    Á¦ÇÑ
  • restriction endonuclease
    Á¦ÇÑÇٻ곻ºÎ°¡¼öºÐÇØÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Ia restriction
    IaÂ÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • haplotype restriction
    ÁÖÁ¶Á÷ÀûÇÕÇ׿øº¹ÇÕü¿°»öü Â÷À̼ö¹Ý ¸é¿ªÁ¦ÇÑ
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • DNA polymorphism
    DNA ´ÙÇü¼º
  • polymorphism
    ´ÙÇüÁõ
  • polymorphism
    ´ÙÇüÁõ(Òýû¡à÷ñø)
  • polymorphism
    ´ÙÇü¼ºÁõ
  • polymorphism
    ´ÙÇü, ´ÙÇüÅÂ
  • polymorphism
    ´ÙÇü¼º(Òýû¡à÷), ´ÙÇüÇö»ó(Òýû¡úÞßÚ)
  • polymorphism
    ´ÙÇü¼º(Òýúþàõ)
  • F(ab) fragment
    F(ab)Á¶°¢
  • Fab fragment
    Fab ºÐÀý.
  • Fab fragment
    Fab Á¶°¢.
  • Fab fragment
    Fab ºÐÀý
  • Length constant
    ±æÀÌÁö¼ö(¡­ò¦â¦)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇѼ¼Æí±æÀÌ´ÙÇü¼º(ð¤ùÚ¼¼Æí¡­Òýû¡à÷)
  • restriction fragment length polymorphism,in cystic fibrosis
    ³¶¼º¼¶À¯Áõ(ÀÇ)¡­(Ò¥àõàéë«ñø¡­)
  • restriction fragment length polymorphism analysis
    Á¦ÇÑÀý´Ü±æÀÌ´ÙÇüÁõºÐ¼®
  • restriction fragment length polymorphism=RFLP
    Á¦ÇÑÀýÆí±æÀ̴پ缺
  • pharmacogenetic polymorphism
    ¾à¹°À¯ÀüÇÐÀû ´ÙÇü¼º.
  • polymorphism
    ´ÙÇü, ´ÙÇüÅÂ
  • polymorphism
    ´ÙÇü¼º(Òýû¡à÷), ´ÙÇüÇö»ó(Òýû¡úÞßÚ)
  • polymorphism
    ´ÙÇü¼º(Òýúþàõ)
  • polymorphism
    ´ÙÇüÁõ
  • polymorphism
    ´ÙÇüÁõ(Òýû¡à÷ñø)
  • polymorphism
    ´ÙÇü¼ºÁõ
  • acentric fragment
    ¿°»öü´ÜÆí, ¹«Áß½Éü´ÜÆí
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • bone fragment
    °ñÆí(Íéø¸), °ñ Á¶°¢.
  • detached fragment
    À¯¸®(°ñ)Æí(ë´ìÆÍéø¸).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑ Á¶°¢±æÀÌ ´ÙÇü¼º(Òýúþàõ)
  • restriction polymorphism
    Á¦ÇÑ ´ÙÇü¼º(Òýúþàõ)
  • fragment length mapping
    Á¶°¢ ±æÀÌ ÀÛµµ(íÂÓñ)
  • restriction fragment
    Á¦ÇÑ Á¶°¢
  • DNA polymorphism
    DNA ´ÙÇü¼º(Òýúþàõ) (ÔÒ) restriction fragment length polymorphism
  • polymorphism
    ´ÙÇü¼º(Òýúþàõ)
  • bond length
    °áÇÕ(Ì¿ùê)±æÀÌ
  • chain length
    »ç½½ ±æÀÌ
  • contour length
    ½ÅÀå(ãßíþ)±æÀÌ
  • equivalent chain length
    µî(Ôõ)»ç½½ ±æÀÌ
  • Kuhn statistical length
    Äï Åë°èÀû(÷ÖͪîÜ)±æÀÌ
  • minimal stable length
    ÃÖ¼Ò¾ÈÁ¤(õÌá³äÌïÒ) ±æÀÌ
  • triple-chain length
    »ï(ß²)»ç½½ ±æÀÌ
  • DNA restriction enzyme
    DNA Á¦ÇÑ È¿¼Ò(ð¤ùÚý£áÈ) (ÔÒ) restriction enzyme
  • host-controlled restriction
    ¼÷ÁÖÁ¦¾î Á¦ÇÑ(âÖñ«ð¤åÙð¤ùÚ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction
    ÇÑ, Á¦ÇÑ
  • bone fragment
    °ñÆí
  • fragment
    ¼¼Æí, ÆÄÆí, ´ÜÆí, ºÐÀý, ÆíÀý, °ñÆí
  • gelfoam fragment
    Á©Æû Á¶°¢
  • crown rump length
    µÎÁ¤µÐºÎ±æÀÌ
  • echo train length
    ¿¡ÄÚ¿­±æÀÌ
  • focal length
    ÃÊÁ¡±æÀÌ
  • quarter wave length matching
    4ºÐÇÒÆÄÁ¶È­
  • spatial pulse length
    °ø°£ÆÞ½º±æÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RELP restriction fragment length polymorphism
RFLP restriction fragment length polymorphism
RFLPs Restriction Fragment Length Polymorphisms; Á¦ÇÑÈ¿¼Ò´ÜÆíÀå´ÙÇü
RELV restriction fragment length variant
FL fatty liver; feline leukemia; femur length; fibers of Luschka; fibroblast-like; filtration leukapher...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RFLP PCR)-Restriction fragment length polymorphism
PCR-RFLP Polymerase Chain Reaction-Restriction Fragment Length Polymorphism
RFLP Restriction Fragment Length Polymorphism
RFLP restriction enzyme fragment length polymorphism
RFLP Restriction fragment length polymorphism analysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • polymorphism
    ´ÙÇü, ´ÙÇüÁõ, ´ÙÇü¼º, ´ÙÇü Çö»ó
    °°Àº È­ÇÐ Á¶¼ºÀ» °®Áö¸¸, °áÁ¤ ±¸Á¶¸¦ ´Þ¸®ÇÏ´Â ¹°Áú. µ¿Áú ´ÙÇü ¶Ç´Â µ¿Áú ´Ù»óÀ̶ó°íµµ ÇÑ´Ù.
  • extracapsular restriction
    °üÀý³¶¿Ü Á¦ÇÑ, °üÀý³¶¿Ü °³±¸ Á¦ÇÑ
  • restriction
    °³±¸ Á¦ÇÑ, Á¦ÇÑ
  • amino fragment
    ¾Æ¹Ì³ë ÀýÆí
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • bone fragment
    °ñÆí
  • carboxy fragment
    ź¼Ò ÀýÆí
  • detached fragment
    À¯¸®Æí, À¯¸® °ñÆí
  • enkephalin fragment
    ¿£ÄÉÆÈ¸° ºÐÀý
  • fracture fragment
    °ñÀý Æí
  • fragment
    ºÐÀý, ¼¼Æí, ÆÄÆí, ´ÜÆí, ÆíÀý, °ñÆí
    Å« Àüü°¡ ÆÄ±«µÇ¾î Çü¼ºµÈ ¼ÒÆí.
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • prodynorphin-derived fragment
    ÇÁ·Î´ÙÀ̳븣ÇÉ À¯·¡ ºÐÀý
  • root fragment
    Ä¡±Ù ÆÄÆí, Ä¡±Ù ÀýÆí
  • average length of life
    Æò±Õ ¼ö¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
restriction fragment length polymorphism <molecular biology, technique> A method that allows familial relationships to be established by comparing the characteristic polymorphic patterns that are obtained when certain regions of genomic DNA are amplified (typically by PCR) and cut with certain restriction enzymes.
The variation in the length of DNA fragments produced by a restriction endonuclease that cuts at a polymorphic locus. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.
This is a key tool in DNA fingerprinting, reflecting the existence of different alleles in the individual. Restriction fragment length polymorphism mapping is also used in plant breeding to see if a key trait such as disease resistance is inherited.
In principle, an individual can be identified unambiquously by restriction fragment length polymorphism hence the use of restriction fragment length polymorphism in forensic analysis of blood, hair or semen).
Similarly, if a polymorphism can be identified close to the locus of a genetic defect, it provides a valuable marker for tracing the inheritance of the defect.
Synonym: DNA fingerprinting.
Acronym: RFLP
(12 Jan 1998)
amplified fragment length polymorphism <technique> Invented by KeyGene, a Dutch biotech company based in Wageningen, Holland. The technique is now merchandised under licence agreement by Perkin Elmer.
Selected markers are amplified in a PCR, which makes amplified fragment length polymorphism an easy and fast tool for strain identification in agriculture, botany, microbiology and animal breeding.
Acronym: AFLP
(05 Feb 1998)
restriction length polymorphism Fragment length polymorphism, the existence of allelic forms recognizable by the length of fragments that result when the nucleotide chain is treated by a specific restriction enzyme that cleaves wherever a particular sequence of nucleotides occurs. A mutation in this sequence changes cleaving and hence the number of fragments.
(05 Mar 2000)
restriction-site polymorphism DNA polymorphism in which the sequence of one form of the polymorphism contains a recognition site for a particular endonuclease, but the sequence of the other form lacks such a site.
(05 Mar 2000)
restriction fragment <molecular biology> The fragments of DNA generated by digesting DNA with a specific restriction endonuclease. Each of the fragments ends in a site recognised by that specific enzyme.
(10 Mar 1998)
balanced polymorphism <genetics> A type of polymorphism where the many morphs are alleles. The polymorphism is maintained in a population rather than the norm of one allele eventually becoming the only allele in the population, because individuals who are heterozygous, or have two different alleles, are more adaptive (more fit) than individuals who are homozygous, or have two copies of the same allele.
(09 Oct 1997)
genetic polymorphism The occurrence in the same population of multiple discrete alletic states of which at least two have high frequency (conventionally of 1% or more).
(05 Mar 2000)
corneal endothelial polymorphism A greater than normal variation in the shape of the cells.
(05 Mar 2000)
polymorphism 1. <genetics> The regular and simultaneous occurrence in a single interbreeding population of two or more alleles of a gene, where the frequency of the rarer alleles is greater than can be explained by recurrent mutation alone (typically greater than 1%). The concept includes chromosome polymorphism.
HLA alleles of the major histocompatibility complex are very polymorphic.
2. <zoology> The differentiation of various parts of the units of colonial animals into different types of unit specialised for different purposes, for example as in the colonial hydroid Obelia.
(04 Jul 1999)
polymorphism, single-stranded conformational Variation occurring within a species in the conformation of denatured DNA fragments. These single-stranded DNA fragments are allowed to partially renature in a way that prevents the formation of double-stranded DNA. The fragments are run on polyacrylamide gels under various conditions to detect subtle changes in migration due to altered secondary structure. The resulting bands will align themselves if the fragments are the same, but will misalign if any point mutations are present. Sscps have been used in detecting mutations in various genes, such as oncogenes, tumour suppressor genes, and genes responsible for genetic diseases.
(12 Dec 1998)
single stranded conformational polymorphism Technique for detecting point mutations in genes by amplifying a region of genomic DNA (using asymmetric PCR) and running the resulting product on a high quality gel. Single base substitutions can alter the secondary structure of the fragment in the gel, producing a visible shift in its mobility.
(18 Nov 1997)
DNA polymorphism A condition in which one of two different but normal nucleotide sequences can exist at a particular site in DNA.
(05 Mar 2000)
lipoprotein polymorphism Heritable variations in low density beta-lipoproteins; the variant lipoproteins exhibit different antigenic and chemical properties when compared with normal lipoproteins.
(05 Mar 2000)
acentric fragment A fragment of a chromosome lacking a centromere and unable to attach to the mitotic spindle, therefore unable to take part in the division of a nucleus and randomly distributed in daughter cells.
Synonym: acentric fragment.
(05 Mar 2000)
Brimacombe fragment A ribonucleoprotein fragment obtained by mild ribonuclease treatment of ribosomes.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Polymorphism, Restriction Fragment Length - »õâ Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment.
    Synonyms :
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymorphism
    ´ÙÇü;µ¿Áú ÀÌ»ó;µ¿Áú ´Ù»ó
  • fission fragment
    Çٺп­ÀÇ ÆÄÆí
  • fragment
    ÆÄÆí;´ÜÆí;¹Ì¿Ï¼º À¯°í;ºÎ¼­Áø Á¶°¢;»ê»êÀÌ ºÎ¼ö´Ù;»ê»ê Á¶°¢ÀÌ µÇ´Ù;ºÎ¼­Áö´Ù
  • restriction
    Á¦ÇÑ
  • import restriction
    ¼öÀÔÁ¦ÇÑ(±ÔÁ¦)
  • restriction
    Á¦ÇÑ;ÇÑÁ¤;±¸¼Ó;¼Ó¹Ú;Á¦ÇÑ(Á¦¾à)ÇÏ´Â °Í;»ç¾ç
  • restriction endonuclease
    =RESTRICTION ENZYME
  • restriction enzyme
    Á¦ÇÑ È¿¼Ò(µÎÁÙ »ç½½ DNA¸¦ ƯÁ¤ ºÎÀ§¿¡¼­ Àý´ÜÇÏ´Â È¿¼Ò)
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
  • at length
    µåµð¾î, »ó¼¼È÷, ÃæºÐÈ÷
  • length
    ±æÀÌ
  • cable('s) length
    ¿¬(100-120±æ(fathoms);¾à 185m)
  • field length
    ÀÌÂø·ú ȰÁÖ °Å¸®
  • focal length
    ÃÊÁ¡°Å¸®
  • graduated length method
    Á¡Â÷Àû ±æÀÌ º¯°æ¹ý(±â¼úÀÇ Çâ»ó¿¡ µû¶ó ½ºÅ°¸¦ ±ä °ÍÀ¸·Î Á¡Â÷ ¹Ù²Ù¾î °¡´Â ½ºÅ° Áöµµ¹ý)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á